NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life

Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Offering, the Company’s sponsors (affiliates of Warburg Pincus and GTCR) will cease to own a majority of the Company’s outstanding common stock, which will affect certain sponsor rights and related matters. These rights are described in the Company’s most recently filed annual general meeting proxy statement. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the… 

Avive Clinic Brisbane, a leading provider of mental health services, is transforming the landscape of drug rehabilitation with its cutting-edge approach to treatment. Addressing the complex challenges of substance use disorders, Avive Clinic Brisbane combines innovative therapies, state-of-the-art facilities, and a patient-centric approach to support individuals on their entire journey to recovery. For more information visit: https://avivehealth.com.au/conditions-we-treat/substance-use-disorders. Substance use disorders are debilitating conditions affecting millions worldwide. They can disrupt every aspect of a person’s life, impacting their physical and mental health, relationships, and overall well-being. Avive Clinic Brisbane recognises the diverse nature of substance use disorders and the need for personalised treatment plans. The clinic’s multidisciplinary team of mental health professionals, including psychiatrists, psychologists, therapists, and addiction specialists, collaborate to design comprehensive programs tailored to each individual’s unique needs. They understand that addiction is a complex issue with no one-size-fits-all… 

Medical Robot Market Set to Achieve 12.9% CAGR, Projected to Reach USD 38,701.5 Million by 2034 Due to Advancements in Robot-Assisted Surgery. The global medical robot market is set to witness unprecedented growth over the next decade, with its market size expected to surge from USD 11,502.4 million in 2024 to a staggering USD 38,701.5 million by 2034. This growth trajectory, reflecting a CAGR of 12.9%, is driven by technological advancements, increased demand for minimally invasive surgeries, and the rising adoption of robotics in healthcare. Understanding the Medical Robot Market: The Medical Robot Market encompasses a range of robotic systems and devices designed to assist medical professionals in various tasks, including surgical procedures, rehabilitation, diagnostics, and patient care. These robots offer enhanced precision, reduced recovery times, and the ability to perform complex procedures with minimal human intervention. As the healthcare… 

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the U.S., Europe, and internationally. The Allegations: Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine According to the complaint, the Company’s products include, inter alia, mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (“RSV”) vaccine, intended to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Plaintiff alleges that during the class period, defendants failed to disclose that:… 

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. The offering is expected… 

The global squalene industry generated $114.5 million in 2020, and is estimated to reach $241.6 million by 2030, witnessing a CAGR of 7.8% from 2021 to 2030. The squalene market is experiencing robust growth due to rising demand in cosmetics and pharmaceuticals for its moisturizing and anti-aging properties. Increased awareness of natural and sustainable ingredients is driving market expansion. Additionally, innovations in extraction techniques and applications are broadening its industry uses. Allied Market Research published a report, titled, „Squalene Market by Source (Animal, Vegetable, and Synthetic Biotechnology), End Use Industry (Cosmetics, Nutraceuticals, and Healthcare): Global Opportunity Analysis and Industry Forecast, 2021–2030.“ Squalene is a colorless, oily triterpene hydrocarbon that is found in many animals and plants, including sharks, olives, and sugarcane. Drivers, Restraints, and Opportunities:Rise of the cosmetics industry, surge in value and potential of dietary supplements, and usage of… 

The first real-world analysis of tinnitus patients treated with Lenire in the United States has been submitted to a journal for peer-review and is now available on an online pre-print server for health services, medRxiv.Real-world results are consistent with Lenire’s large-scale clinical trial results.91.5% of patients experienced clinically meaningful reduction in tinnitus after 12-weeks of treatment with Lenire.89.2% of patients indicated they benefited from treatment with Lenire.220 patient treatment results were analyzed for the review making the paper one of the largest real-world analyses of tinnitus patients ever conducted.

Die Aufwendungen der Arztpraxen in Deutschland haben im Jahr 2022 um 11,0 Prozent gegenüber dem Vorjahr zugenommen. In einem Umfeld stark gestiegener Verbraucherpreise erhöhten sich die durchschnittlichen Aufwendungen je Arztpraxis im Jahr 2022 auf 466.000 Euro (2021: 420.000 Euro), teilte das Statistische Bundesamt am Dienstag mit. Zu den Arztpraxen zählen Einzelpraxen, fachgleiche sowie fachübergreifende Berufsausübungsgemeinschaften […] Aufwendungen von Arztpraxen stark gestiegen